SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for Poster Presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024).

中国苏州和马里兰州罗克维尔，2024年5月15日/PRNewswire/--Ascentage Pharma（6855.HK），一家致力于开发癌症、慢性乙型肝炎（CHB）和年龄相关疾病新疗法的全球生物制药公司，今天宣布，五项研究的最新结果已被选为2024年欧洲血液学协会混合大会（EHA 2024）的海报展示。

These posters will feature olverembatinib (HQP1351), the first and only China-approved third-generation BCL-ABL1 inhibitor; investigational lisaftoclax (APG-2575), a Bcl-2 selective inhibitor; and investigational APG-5918, an EED selective inhibitor..

这些海报将以olverembatinib（HQP1351）为特色，olverembatinib是中国第一个也是唯一一个批准的第三代BCL-ABL1抑制剂；研究性lisaftoclax（APG-2575），一种Bcl-2选择性抑制剂；和EED选择性抑制剂APG-5918的研究。。

The European Hematology Association (EHA) Hybrid Congress is the largest gathering of the hematology field in Europe. It showcases the most cutting-edge research and state-of-the-art innovative therapies, attracting over 10,000 clinical experts and researchers from more than 100 countries every year.

欧洲血液学协会（EHA）混合大会是欧洲血液学领域最大的集会。它展示了最前沿的研究和最先进的创新疗法，每年吸引来自100多个国家的10000多名临床专家和研究人员。

This year, the EHA Hybrid Congress will take place on June 13 - 16, 2024, in Madrid, Spain..

今年，EHA混合动力大会将于2024年6月13日至16日在西班牙马德里举行。。

'I am delighted to showcase the strength and progress of Ascentage Pharma in hematology at this year's congress, especially the therapeutic potential and clinical value of its drug candidates in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia diseases,' said Dr.

“我很高兴在今年的大会上展示Ascentage Pharma在血液学方面的优势和进展，特别是其候选药物在慢性粒细胞白血病（CML），费城染色体阳性急性淋巴细胞白血病（Ph+ALL），多发性骨髓瘤（MM），免疫球蛋白轻链（AL）淀粉样变性和贫血疾病中的治疗潜力和临床价值，”Dr。

Yifan Zhai, Chief Medical Officer of Ascentage Pharma. 'We look forward to sharing the detailed results at the congress. In the future, we will continue to advance those development programs in efforts to bring more treatment options to patients around the world.'.

Ascentage Pharma首席医疗官翟一凡（音）我们期待着在大会上分享详细的结果。未来，我们将继续推进这些发展计划，努力为世界各地的患者带来更多的治疗选择。”。

The five studies to be presented at EHA 2024 are as follows:

将在2024年EHA上提交的五项研究如下：

Olverembatinib

奥列姆巴蒂尼

Olverembatinib Overcomes Ponatinib and Asciminib Resistance in Patients (Pts) with Heavily Pretreated Chronic Myeloid Leukemia (CML) and Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Olverembatinib克服了重度预处理的慢性粒细胞白血病（CML）和费城阳性急性淋巴细胞白血病（Ph⁺ 全部）

• Abstract#: P722

•摘要#：P722

• Presentation Type: Poster presentation

•展示类型：海报展示

• Topic: Chronic myeloid leukemia – Clinical

•主题：慢性粒细胞白血病-临床

• Date & Time: Friday June 14, 2024, 18:00 - 19:00 CEST

•日期和时间：2024年6月14日星期五，CEST 18:00-19:00

• Presenting Author: Dr. Elias Jabbour, The University of Texas MD Anderson Cancer Center

•演示作者：德克萨斯大学安德森癌症中心Elias Jabbour博士

Combination of Third Generation TKI Olverembatinib and Chemotherapy or Blinatumomab for New Diagnosed Adult Ph+ ALL Patients

第三代TKI Olverembatinib联合化疗或Blinatumomab治疗新诊断的成人Ph+ALL患者

• Abstract#: P427

•摘要#：P427

• Presentation Type: Poster presentation

•展示类型：海报展示

• Topic: Acute lymphoblastic leukemia – Clinical

•主题：急性淋巴细胞白血病-临床

• Date & Time: Friday June 14, 2024, 18:00 - 19:00 CEST

•日期和时间：2024年6月14日星期五，CEST 18:00-19:00

• Presenting Author: Junjie Chen, Nanfang Hospital, Southern Medical University

•报告作者：陈俊杰，南方医科大学南方医院

Patient Reported Outcomes in Adults with TKI-Resistant Chronic Myeloid Leukemia Receiving Olverembatinib-Therapy

接受Olverembatinib治疗的TKI耐药慢性粒细胞白血病成人患者报告的结果

• Abstract#: P1862

•摘要#：P1862

• Presentation Type: e-Poster presentation

•演示类型：电子海报演示

• Topic: Chronic myeloid leukemia – Clinical

•主题：慢性粒细胞白血病-临床

• Date & Time: Friday June 14, 2024, 18:00 - 19:00 CEST

•日期和时间：2024年6月14日星期五，CEST 18:00-19:00

• Presenting Author: Lu Yu, Peking University People's Hospital

•演示作者：北京大学人民医院陆宇

Lisaftoclax

Lisaftoclax

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (Pts) with Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Lisaftoclax（APG-2575）联合新的治疗方案治疗复发或难治性（R/R）多发性骨髓瘤（MM）或免疫球蛋白轻链（AL）淀粉样变性患者

• Abstract#: P917

•摘要#：P917

• Presentation Type: Poster presentation

•展示类型：海报展示

• Topic: Myeloma and other monoclonal gammopathies – Clinical

•主题：骨髓瘤和其他单克隆丙种球蛋白病-临床

• Date & Time: Friday June 14, 2024, 18:00 - 19:00 CEST

•日期和时间：2024年6月14日星期五，CEST 18:00-19:00

• Presenting Author: Dr. Sikander Ailawadhi, Mayo Clinic Florida

•演示作者：佛罗里达州梅奥诊所Sikander Ailawadhi博士

APG-5918

APG-5918

Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Improves Chronic Kidney Disease- (CKD)-Induced Hemoglobin (HB) Insufficiency in Preclinical Models of Anemia

胚胎外胚层发育（EED）抑制剂APG-5918改善贫血临床前模型中慢性肾病（CKD）诱导的血红蛋白（HB）不足

• Abstract#: P1550

•摘要#：P1550

• Presentation Type: Poster presentation

•展示类型：海报展示

• Topic: Enzymopathies, membranopathies and other anemias

•主题：酶病，膜病和其他贫血

• Date & Time: Friday June 14, 2024, 18:00 - 19:00 CEST

•日期和时间：2024年6月14日星期五，CEST 18:00-19:00

• Presenting Author: Dr. Eric Liang, Ascentage Pharma Group Inc.

•演示作者：Eric Liang博士，Ascentage Pharma Group Inc。

About Ascentage Pharma

关于Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK..

Ascentage Pharma（6855。HK）是一家专注于全球的生物制药公司，致力于开发针对癌症，慢性乙型肝炎和与年龄有关的疾病的新型疗法。2019年10月28日，Ascentage Pharma在香港联合交易所主板上市，股票代码6855.HK。。

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Ascentage Pharma专注于开发抑制蛋白质-蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司已经建立了9种临床候选药物的管道，包括新型高效Bcl-2和双重Bcl-2/Bcl-xL抑制剂，以及针对IAP和MDM2-p53途径的候选药物，以及下一代酪氨酸激酶抑制剂（TKIs）。

Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials, including 5 global registrational phase III studies, in the US, Australia, Europe, and China.

Ascentage Pharma也是世界上唯一一家针对所有三类已知的关键凋亡调节剂开展积极临床计划的公司。该公司正在美国、澳大利亚、欧洲和中国进行40多项I/II期临床试验，包括5项全球注册III期研究。

Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases..

Ascentage Pharma已被指定参与多项重大国家研发项目，包括五个重大新药项目、一个新药孵化器项目、四个创新药物项目和一个传染病防治重大项目。。

Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA).

Olverembatinib是该公司为治疗耐药性慢性粒细胞白血病（CML）而开发的核心候选药物，也是该公司首个获批产品，已被中国国家医药产品管理局（NMPA）药物评估中心（CDE）授予优先审查指定和突破性治疗指定。

To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates..

迄今为止，该药物已被纳入中国2022年国家报销药物清单（NRDL）。此外，olverembatinib已被美国FDA授予孤儿药名称（ODD）和快速通道名称（FTD），并被欧盟EMA授予孤儿名称。迄今为止，Ascentage Pharma已经从美国FDA获得了16个赔率，并从欧盟EMA获得了1个孤儿指定，用于该公司的4个研究候选药物。。

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca.

凭借强大的研发能力，Ascentage Pharma建立了全球知识产权组合，并与众多知名生物技术和制药公司以及研究机构建立了全球合作伙伴关系，如UNITY biotechnology、MD Anderson癌症中心、Mayo Clinic、Dana Farber癌症研究所、MSD和AstraZeneca。

The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients..

该公司建立了一支在创新药物的发现和开发方面具有全球经验的人才团队，并正在建立其世界一流的商业制造和销售与营销团队。Ascentage Pharma的一个关键目标是不断加强其研发能力，加速其临床开发计划，以实现其解决中国和世界各地未满足的临床需求的使命，造福更多患者。。

Forward-Looking Statements

前瞻性声明

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

本文所作的前瞻性陈述仅与截至本文所作陈述之日的事件或信息有关。除法律要求外，Ascentage Pharma没有义务在声明发布之日后，由于新信息、未来事件或其他原因，或为了反映意外事件的发生，公开更新或修改任何前瞻性声明。

You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article.

您应该完整阅读本文，并了解我们未来的实际结果或表现可能与我们预期的有实质性差异。在本文中，我们或我们的任何董事或我们公司的意图的陈述或引用是在本文日期做出的。

Any of these intentions may alter in light of future development..

这些意图中的任何一个都可能根据未来的发展而改变。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/eha-2024--results-from-five-studies-of-ascentage-pharmas-key-drug-candidates-selected-for-presentations-at-2024-european-hematology-association-hybrid-congress-302147047.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/eha-2024--results-from-five-studies-of-ascentage-pharmas-key-drug-candidates-selected-for-presentations-at-2024-european-hematology-association-hybrid-congress-302147047.html

SOURCE Ascentage Pharma

来源：Ascentage Pharma

Company Codes: HongKong:6855

公司代码：香港：6855